Medivir AB (MVIRb.F) Release: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain
10/10/2013 9:36:05 AM
Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that MIV-247 has been
selected as a candidate drug (CD) from its cathepsin S inhibitor project for the
treatment of neuropathic pain, and is entering non-clinical development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by